Research
Nanobody Shows Promise in Myasthenia Gravis
The Brief
- Results from the phase III PREVAIL trial were presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting.
- The investigational drug is gefurulimab, a nanobody given once weekly.
- The source excerpt reports a significant result but is truncated, so the outcome details are not confirmed here.
Why it matters
It reports phase III data for a once-weekly nanobody in myasthenia gravis, a signal for neurology researchers following antibody-based treatments for this autoimmune disease.
Who’s affected
- neurologists and neuromuscular clinicians
- people with myasthenia gravis and their caregivers
- #myasthenia gravis
- #nanobody
- #gefurulimab
- #clinical trial
- #neurology
(MedPage Today) -- Results from the phase III PREVAIL trial presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that treatment with the investigational once-weekly nanobody gefurulimab significantly...